Evidence map›Paper›PMID 39696387›Full record

ArticleMalaria journal2024

Asymptomatic Plasmodium falciparum infections and determinants of carriage in a seasonal malaria chemoprevention setting in Northern Cameroon and south Senegal (Kedougou).

Innocent M Ali, Isaac A Manga, Akindeh M Nji, Valery P Tchuenkam, Peter Thelma Ngwa Neba, Dorothy F Achu, Jude D Bigoga, Babacar Faye, Cally Roper, Colin J Sutherland and 1 more

Abstract read
In one paragraph

Article in Malaria journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Innocent M AliMARCAD Programme, The Biotechnology Centre, University of Yaoundé 1, Yaoundé, Cameroon. dr.alinn@gmail.com.
Isaac A MangaDepartment of Parasitology and Mycology, Faculty of Medicine and Odontostomatology, Université Cheick Anta Diop, Dakar, Senegal.
Akindeh M NjiMARCAD Programme, The Biotechnology Centre, University of Yaoundé 1, Yaoundé, Cameroon.
Valery P TchuenkamDepartment of Biochemistry, University of Dschang, Dschang, Cameroon.
Peter Thelma Ngwa NebaMARCAD Programme, The Biotechnology Centre, University of Yaoundé 1, Yaoundé, Cameroon.
Dorothy F AchuNational Malaria Control Programme, Ministry of Public Health, Yaoundé, Cameroon.
Jude D BigogaMARCAD Programme, The Biotechnology Centre, University of Yaoundé 1, Yaoundé, Cameroon.
Babacar FayeDepartment of Parasitology and Mycology, Faculty of Medicine and Odontostomatology, Université Cheick Anta Diop, Dakar, Senegal.
Cally RoperDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Colin J SutherlandDepartment of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Wilfred F MbachamMARCAD Programme, The Biotechnology Centre, University of Yaoundé 1, Yaoundé, Cameroon. wfmbacham@yahoo.com.

Funding

Wellcome TrustWellcome Trust grant # 107741/A/15/Z
6 · The paper itself

Abstract

backgroundAmong the several strategies recommended for the fight against malaria, seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine combination (SPAQ) targets children 3 months to 5 years in Sahel regions of Africa to reduce mortality and mortality. Since SMC with SPAQ is administered to symptoms-free children for prevention of malaria, it is anticipated that a proportion of asymptomatic parasitaemic children will also be treated and may result in a drop in both the overall population prevalence of asymptomatic malaria infections, subsequent risk of symptomatic malaria infections and transmission. Age-specific carriage of asymptomatic Plasmodium spp. infections (API) was evaluated in target children and adults in Cameroon and Senegal, prior to the 2018 SMC campaign in both countries.

methodsA baseline household survey was carried out in August 2018 in two areas in Cameroon and one in Senegal just before the beginning of distribution of SPAQ for SMC. The survey included collection of fingerpick blood for malaria rapid diagnostic testing (RDT) and administration of a pre-tested questionnaire on demographics and malaria risk factors to participants. The age-specific prevalence of API in all study sites was analysed, first as a distribution of RDT-positives in 5-year age categories and secondly, with age as a continuous variable in the whole sample, using the Wilcoxon rank sum test. Risk factors for carriage of asymptomatic infections were examined using logistic regression analysis in STATA v.16 and Rv4.1.2.

resultsIn total, 6098 participants were surveyed. In Cameroon, overall prevalence of API was 34.0% (32.1-36.0%) in Adamaoua, and 43.5% (41.0-45.7%) in the North. The median age of RDT positivity was higher in Senegal: 11 years (IQR 7-16) than in Cameroon-Adamaoua: 8 years (4-17) and North: 8 years (4-12) and significantly different between the three study regions. In all three study sites, asymptomatic carriage was significantly higher in the older age group (5-10 in Cameroon, and 7-14 in Senegal), compared to the younger age group, although the median age of participants was lower among RDT-negatives in the North compared to RDT-positives. Health area, gender and last infection within past year significantly confounded the relationship between age and parasite carriage in Adamaoua and Senegal but not in North Cameroon. Absence of bed net and previous infection within one month of the survey all independently predicted carriage of asymptomatic parasites in multivariate regression analysis.

conclusionUnder five years asymptomatic Plasmodium infection in northern Cameroon prior to SMC season remained high in 2018, irrespective of history of SMC implementation in the study areas in Cameroon. Compared to Adamaoua, peak asymptomatic malaria parasite rate was observed in children 5-10 years, which is out of the SMC target age-range. Health area, last infection within the past month and to a lesser extent gender affected the association between age and asymptomatic carriage in all sites except the North region of Cameroon, indicating wide heterogeneity in risk of malaria among the general population in that geography. Follow-up studies designed to measure SMC effects in Cameroon are warranted as it may become necessary to extend age of SMC eligibility to 10 years, as is practiced in Senegal.

Indexed as

AntimalarialsAsymptomatic InfectionsCarrier StateChemopreventionMalaria, FalciparumAdolescentAdultAgedAmodiaquineCameroonChildChild, PreschoolDrug CombinationsFemaleHumansInfantAmodiaquineAntimalarialsDrug Combinationsfanasil, pyrimethamine drug combinationPyrimethamineSulfadoxineAdamaouaAsymptomatic malariaKedougouPlasmodiumSeasonal malaria chemoprevention

Identifiers

PMID39696387
PMCPMC11657642

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.